These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16170240)

  • 1. Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program.
    Warren E; Anderson R; Proos AL; Burnett LB; Barlow-Stewart K; Hall J
    Genet Med; 2005 Sep; 7(7):484-94. PubMed ID: 16170240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
    Kronn D; Jansen V; Ostrer H
    Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students.
    Barlow-Stewart K; Burnett L; Proos A; Howell V; Huq F; Lazarus R; Aizenberg H
    J Med Genet; 2003 Apr; 40(4):e45. PubMed ID: 12676918
    [No Abstract]   [Full Text] [Related]  

  • 4. The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program.
    Rozenberg R; Pereira Lda V
    Sao Paulo Med J; 2001 Jul; 119(4):146-9. PubMed ID: 11500789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews.
    Lew RM; Proos AL; Burnett L; Delatycki M; Bankier A; Fietz MJ
    Med J Aust; 2012 Dec; 197(11):652-4. PubMed ID: 23230938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.
    Hussein N; Weng SF; Kai J; Kleijnen J; Qureshi N
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010849. PubMed ID: 26264938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.
    Hussein N; Weng SF; Kai J; Kleijnen J; Qureshi N
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD010849. PubMed ID: 29537064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease.
    Colaianni A; Chandrasekharan S; Cook-Deegan R
    Genet Med; 2010 Apr; 12(4 Suppl):S5-S14. PubMed ID: 20393311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-specific screening by mutation analysis for diseases frequent in Ashkenazi Jews.
    DeMarchi JM; Caskey CT; Richards CS
    Hum Mutat; 1996; 8(2):116-25. PubMed ID: 8844209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimedia messages in genetics: design, development, and evaluation of a computer-based instructional resource for secondary school students in a Tay Sachs disease carrier screening program.
    Gason AA; Aitken M; Delatycki MB; Sheffield E; Metcalfe SA
    Genet Med; 2004; 6(4):226-31. PubMed ID: 15266211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A re-examination of the use of ethnicity in prenatal carrier testing.
    Ross LF
    Am J Med Genet A; 2012 Jan; 158A(1):19-23. PubMed ID: 22106058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACOG committee opinion. Number 298, August 2004. Prenatal and preconceptional carrier screening for genetic diseases in individuals of Eastern European Jewish descent.
    ACOG Committee on Genetics
    Obstet Gynecol; 2004 Aug; 104(2):425-8. PubMed ID: 15292027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical Issues with Genetic Testing for Tay-Sachs.
    Clayton T
    J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tay Sachs disease carrier screening in schools: educational alternatives and cheekbrush sampling.
    Gason AA; Metcalfe SA; Delatycki MB; Petrou V; Sheffield E; Bankier A; Aitken M
    Genet Med; 2005; 7(9):626-32. PubMed ID: 16301864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and beta-thalassemia.
    Laberge AM; Watts C; Porter K; Burke W
    Public Health Genomics; 2010; 13(5):310-9. PubMed ID: 19864874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal genetic carrier testing using triple disease screening.
    Eng CM; Schechter C; Robinowitz J; Fulop G; Burgert T; Levy B; Zinberg R; Desnick RJ
    JAMA; 1997 Oct; 278(15):1268-72. PubMed ID: 9333269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools.
    Mitchell JJ; Capua A; Clow C; Scriver CR
    Am J Hum Genet; 1996 Oct; 59(4):793-8. PubMed ID: 8808593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carrier screening for Tay-Sachs disease and cystic fibrosis.
    ten Kate LP; Tijmstra T
    Lancet; 1990 Jun; 335(8704):1527-8. PubMed ID: 1972454
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethical aspects of genetic screening in Israel.
    Sagi M
    Sci Context; 1998; 11(3-4):419-29. PubMed ID: 15168671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis.
    Vintzileos AM; Ananth CV; Smulian JC; Fisher AJ; Day-Salvatore D; Beazoglou T
    Obstet Gynecol; 1998 Apr; 91(4):529-34. PubMed ID: 9540935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.